DaVita Inc
XMUN:TRL
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
D
|
DaVita Inc
XMUN:TRL
|
US |
|
C
|
Chayo Group PCL
SET:CHAYO
|
TH |
|
F
|
Ford Motor Co
XMUN:FMC1
|
US |
|
Floor & Decor Holdings Inc
NYSE:FND
|
US |
|
C
|
Corning Inc
XMUN:GLW
|
US |
DaVita Inc
DaVita is a healthcare company focused on kidney care. Its main business is running dialysis centers, where it treats patients whose kidneys can no longer clean waste from the blood properly. It also offers related care services for people with chronic kidney disease, including support before dialysis starts and help managing long-term treatment. The company makes most of its money by billing health insurers, government programs, and other payers for dialysis treatments and related care. Its main customers are patients with kidney failure and the healthcare systems that cover their treatment, especially those who need repeat, ongoing care rather than a one-time service. Because dialysis is usually needed several times a week, DaVita’s business is built around steady, recurring patient visits. What makes DaVita’s role distinct is that it sits in a very specific and essential part of the healthcare chain: it turns kidney disease treatment into a large-scale service network. Instead of selling a product, it provides a specialized medical service that depends on trained staff, clinic operations, and close coordination with doctors and insurers. That makes it a focused operator in a niche but critical area of healthcare.
DaVita is a healthcare company focused on kidney care. Its main business is running dialysis centers, where it treats patients whose kidneys can no longer clean waste from the blood properly. It also offers related care services for people with chronic kidney disease, including support before dialysis starts and help managing long-term treatment.
The company makes most of its money by billing health insurers, government programs, and other payers for dialysis treatments and related care. Its main customers are patients with kidney failure and the healthcare systems that cover their treatment, especially those who need repeat, ongoing care rather than a one-time service. Because dialysis is usually needed several times a week, DaVita’s business is built around steady, recurring patient visits.
What makes DaVita’s role distinct is that it sits in a very specific and essential part of the healthcare chain: it turns kidney disease treatment into a large-scale service network. Instead of selling a product, it provides a specialized medical service that depends on trained staff, clinic operations, and close coordination with doctors and insurers. That makes it a focused operator in a niche but critical area of healthcare.
In line: DaVita said second quarter results were broadly in line with expectations, with adjusted operating income of $579 million, adjusted EPS of $4.02 and free cash flow of $256 million.
Volume strength: U.S. treatment growth accelerated slightly above plan, helped mainly by better mortality trends and partly offset by fewer clinic closures benefits and a bit more missed treatments.
Mix pressure: Revenue per treatment fell sequentially because of lower commercial mix tied to ACA exchange enrollment and lower phosphate binder revenue, and management still expects full-year pressure from those trends.
Guidance held: The company reaffirmed full-year 2026 guidance, keeping the midpoint at $2.2 billion for adjusted operating income and $14.65 for adjusted EPS.
New therapy push: DaVita highlighted expanded HD as a major clinical and operational opportunity, saying it has secured supply and expects broad deployment in coming quarters, but the financial impact should be limited near term.
Policy watch: Management said the proposed 2027 ESRD rule still looks below industry cost trends, while supporting CMS’s move to bundle phosphate binders and end TDAPA after 2 years.